Insider Selling: Brian Quirk Sold 2,000 Shares of MKS Instruments, Inc. (MKSI); Molecular Templates (MTEM) Shorts Increased By 25.47%

Molecular Templates Incorporated (NASDAQ:MTEM) had an increase of 25.47% in short interest. MTEM’s SI was 251,200 shares in February as released by FINRA. Its up 25.47% from 200,200 shares previously. With 70,700 avg volume, 4 days are for Molecular Templates Incorporated (NASDAQ:MTEM)’s short sellers to cover MTEM’s short positions. The stock decreased 9.05% or $0.9 during the last trading session, reaching $9.04. About 119,046 shares traded or 4.57% up from the average. Molecular Templates, Inc. (NASDAQ:MTEM) has 0.00% since February 6, 2017 and is . It has underperformed by 16.70% the S&P500.

As discovered in the Washington-based SEC, a legal report for the deal of 2,000 shares of Mks Instruments Inc by Brian Quirk was filled. Brian Quirk is presently the Sr. VP – Global Operations of the firm. The document was filled on 06-02-2018. The shares were sold at average $105.1 a share, and are with market value of $210,200 US Dollars. Brian Quirk now has 11,863 shares which are exactly 0.02% of the Massachusetts-based company’s market capitalization.

Among 6 analysts covering MKS Instruments (NASDAQ:MKSI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MKS Instruments has $138.0 highest and $42 lowest target. $104.20’s average target is -1.84% below currents $106.15 stock price. MKS Instruments had 12 analyst reports since October 23, 2015 according to SRatingsIntel. Stifel Nicolaus maintained MKS Instruments, Inc. (NASDAQ:MKSI) on Thursday, May 12 with “Buy” rating. Dougherty & Company maintained it with “Buy” rating and $45 target in Monday, May 2 report. On Monday, January 4 the stock rating was initiated by Pacific Crest with “Overweight”. Dougherty & Company maintained it with “Buy” rating and $46 target in Monday, June 13 report. The firm has “Buy” rating given on Thursday, February 1 by Stifel Nicolaus. The firm has “Buy” rating given on Thursday, February 1 by KeyBanc Capital Markets. Citigroup initiated it with “Buy” rating and $59 target in Wednesday, October 12 report. As per Tuesday, January 24, the company rating was upgraded by Dougherty & Company. The stock of MKS Instruments, Inc. (NASDAQ:MKSI) earned “Buy” rating by Dougherty & Company on Friday, October 23. The company was maintained on Wednesday, November 23 by Stifel Nicolaus.

Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.12, from 1.23 in 2017Q2. It is positive, as 21 investors sold MKS Instruments, Inc. shares while 99 reduced holdings. 64 funds opened positions while 98 raised stakes. 51.02 million shares or 0.62% less from 51.34 million shares in 2017Q2 were reported. Phocas Fincl holds 191,304 shares. The Vermont-based Hanson & Doremus has invested 0.27% in MKS Instruments, Inc. (NASDAQ:MKSI). Aperio Group Ltd Liability Company reported 17,130 shares stake. Putnam Invests owns 14,500 shares. Invesco invested in 0.04% or 1.18M shares. Savings Bank Of America Corp De invested in 0% or 219,523 shares. Pitcairn holds 0.11% in MKS Instruments, Inc. (NASDAQ:MKSI) or 10,315 shares. Gotham Asset Management Limited Com holds 0.16% or 116,581 shares in its portfolio. Etrade Ltd Liability Company owns 14,916 shares for 0.05% of their portfolio. Putnam Fl Mngmt Communications has 28,784 shares. California Employees Retirement Sys holds 86,028 shares or 0.01% of its portfolio. Cubic Asset Management Limited Liability Corp stated it has 0.49% in MKS Instruments, Inc. (NASDAQ:MKSI). Capital Mngmt Assocs holds 8,000 shares or 1.08% of its portfolio. Rothschild Asset Management Inc has 0.27% invested in MKS Instruments, Inc. (NASDAQ:MKSI). The Illinois-based Zacks Investment Mngmt has invested 0.07% in MKS Instruments, Inc. (NASDAQ:MKSI).

The stock increased 2.36% or $2.45 during the last trading session, reaching $106.15. About 529,818 shares traded. MKS Instruments, Inc. (NASDAQ:MKSI) has risen 119.33% since February 6, 2017 and is uptrending. It has outperformed by 102.63% the S&P500.

Since August 8, 2017, it had 0 buys, and 7 sales for $3.51 million activity. $963,020 worth of MKS Instruments, Inc. (NASDAQ:MKSI) was sold by COLELLA GERARD G. Another trade for 300 shares valued at $24,840 was made by Mora Elizabeth on Friday, September 1. BAGSHAW SETH H sold $1.02M worth of stock or 10,000 shares. The insider HANLEY PETER sold 300 shares worth $24,945. 2,000 shares were sold by Quirk Brian Charles, worth $158,600 on Tuesday, August 8. Shares for $352,563 were sold by Werth Dennis L on Thursday, December 14.

MKS Instruments, Inc. provides instruments, subsystems, and process control solutions that measure, control, power, deliver, monitor, and analyze critical parameters of manufacturing processes worldwide. The company has market cap of $5.76 billion. The firm operates through two divisions, Vacuum & Analysis and Light & Motion. It has a 17.23 P/E ratio. The Vacuum & Analysis segment provides analytical and control solutions products, including gas analyzers, automation control products, IO modules, automation software, data analytics software, and precision machined components and electromechanical assemblies; and materials delivery solutions products comprising flow and valve technologies, as well as integrated pressure measurement and control subsystems to provide clients with precise control capabilities that are optimized for a given application.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. The company has market cap of $243.13 million. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. It currently has negative earnings.